Business Wire

CA-VELODYNE-LIDAR

13.11.2020 14:02:09 CET | Business Wire | Press release

Share
Velodyne Lidar Unveils Breakthrough Solid State Sensor for Advanced Driver Assistance Systems (ADAS) and Autonomy

Velodyne Lidar, Inc. (Nasdaq: VLDR) today debuted its latest innovation in its broad array of lidar sensors, the Velarray H800. The solid state Velarray H800 is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA). With combined long-range perception and a broad field of view, this sensor is designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. The Velarray H800 will be available at high-volume production levels with a target price of less than $500 to drive broad adoption in consumer and commercial vehicle markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005108/en/

“Velodyne’s launch of the Velarray H800 lidar sensor, which is the first in a family of solid state lidars we will be releasing publicly, is important to automakers for three reasons,” said Anand Gopalan, Velodyne Lidar CEO. “First, the Velarray H800 was specifically designed for high volume automotive applications with feedback from leading OEM customers. It uses Velodyne’s global network of high-quality manufacturing partnerships that provide the high quantity automakers need. Second, Velodyne’s proprietary technology and experience, combined with our manufacturing capacity, allow us to offer the sensor at a price that makes economic sense for automakers. Third, the world needs enhanced safety in consumer vehicles and the Velarray product line makes that available to end consumers creating safer roadways and cars for all.”

The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The World Health Organization reports that annual deaths caused by traffic crashes have reached 1.35 million globally.

“We want to help build the public’s trust in automated vehicle systems,” Marta Hall, Velodyne founder and CMO, commented. “We believe the Velarray H800 is the first of many lidar sensors that will be used in systems for powerful vehicle safety. Velodyne is introducing it as a key sensor for systems designed as building blocks for vehicle safety. Once the public experiences the benefits of reliable automated safety systems, they will welcome more products like this. We can save lives with ADAS.”

The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in autonomy and ADAS, from Level 2 to Level 5. This spans the entirety of ADAS features from Lane Keep Assist and Automated Emergency Braking, all the way to the top levels of automated driving. The compact, low cost sensor can be paired with Velodyne’s Vella software suite, enabling the full spectrum of safety features.

The efficacy of lidar in creating robust and feature-rich ADAS has been acknowledged across the auto industry in the past few years. Proprietary testing indicated superiority of the Velarray-based solution where a traditional camera and radar system failed. Please see Velodyne’s recently issued white paper regarding Pedestrian Automatic Emergency Braking (PAEB) here .

With a field of view of 120 horizontal degrees by 16 vertical degrees, the Velarray H800 allows for outstanding detection of peripheral, near-field, and overhead objects while addressing corner cases on sloping and curving roads. The Velarray H800 provides perception data at a range of up to 200 meters, supporting safe stopping distances even at highway speeds. Featuring a configurable frame rate, the Velarray H800 offers the rich point cloud density required for high resolution mapping and object classification tasks.

Drawing on insights gained from going public, Gopalan commented, “During meetings with investors over the past several months, I have received many questions about Velodyne’s solid state roadmap. The fact is that Velodyne has offered solid state lidar sensors for more than two years, but we’ve used the term ‘directional’ sensors to describe Velodyne’s solid state lidar technology. With the introduction of the Velarray H800, we saw the opportunity to demonstrate how Velodyne’s lidar technology prowess spans many form factors and applications. Velodyne wants to improve roadway safety by making all vehicles smarter. That’s why we are working so hard to provide ADAS technology that can be implemented in the marketplace now. You will soon see more of our sensors and software product releases, offering building blocks of vehicle safety for the public.”

The Velarray H800 is Velodyne’s first new sensor to be launched since the company went public on September 30, 2020. The sensor kicks off the next generation of the company’s solid state lidar portfolio. It complements and leverages Velodyne’s expertise in innovating, building and delivering lidar technology.

About Velodyne Lidar

Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .

Forward Looking Statements

Statements in this release may contain “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “can”, “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; uncertainties related to Velodyne’s estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye